Similar articles

• Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial.

  Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ; GRAVITAS Investigators. Price MJ, et al. JAMA. 2011 Mar 16;305(11):1097-105. doi: 10.1001/jama.2011.290. JAMA. 2011. PMID: 21406646 Clinical Trial.
• Is a 300 mg clopidogrel loading dose sufficient to inhibit platelet function early after coronary stenting? A platelet function profile study.

  Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Hernández-Antolín R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Macaya C. Angiolillo DJ, et al. J Invasive Cardiol. 2004 Jun;16(6):325-9. J Invasive Cardiol. 2004. PMID: 15156004 Clinical Trial.
• Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study.

  Angiolillo DJ, Bernardo E, Palazuelos J, Desai B, Weisberg I, Alfonso F, Guzman LA, Hernández-Antolin R, Zenni MZ, Macaya C, Fernandez-Ortiz A, Bass TA. Angiolillo DJ, et al. Thromb Haemost. 2008 Jan;99(1):161-8. doi: 10.1160/TH07-09-0562. Thromb Haemost. 2008. PMID: 18217149 Clinical Trial.
• Clopidogrel "resistance": where are we now?

  Qureshi Z, Hobson AR. Qureshi Z, et al. Cardiovasc Ther. 2013 Feb;31(1):3-11. doi: 10.1111/j.1755-5922.2011.00296.x. Epub 2011 Aug 3. Cardiovasc Ther. 2013. PMID: 21884029 Review.
• Optimizing platelet P2Y12 inhibition for patients undergoing PCI.

  Steinhubl S, Roe MT. Steinhubl S, et al. Cardiovasc Drug Rev. 2007 Summer;25(2):188-203. doi: 10.1111/j.1527-3466.2007.00013.x. Cardiovasc Drug Rev. 2007. PMID: 17614940 Review.